We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$911M
AUM Growth
-$47.6M
Cap. Flow
-$18.7M
Cap. Flow %
-2.05%
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$18.3M
2
MCK icon
McKesson
MCK
+$8.31M
3
COO icon
Cooper Companies
COO
+$7.22M
4
ABT icon
Abbott
ABT
+$7.18M
5
CI icon
Cigna
CI
+$6.56M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$32.2M
2
JNJ icon
Johnson & Johnson
JNJ
+$17.7M
3
MDT icon
Medtronic
MDT
+$9.37M
4
PFE icon
Pfizer
PFE
+$6.91M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$6.48M

Sector Composition

Rank Sector Weight
1 Healthcare 95.19%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$35.7M 3.92%
76,000
+38,000
+100% +$18.3M
BSX icon
2
Boston Scientific
BSX
$69.5B
$29.8M 3.27%
600,000
+15,000
+3% +$707K
REGN icon
3
Regeneron Pharmaceuticals
REGN
$78.5B
$28.8M 3.16%
35,500
-1,500
-4% -$1.13M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$121B
$26.1M 2.86%
83,500
+3,500
+4% +$1.05M
ELV icon
5
Elevance Health
ELV
$81.5B
$25.7M 2.82%
56,000
+11,000
+24% +$5.23M
MRK icon
6
Merck
MRK
$322B
$25.5M 2.8%
241,000
+26,000
+12% +$2.81M
BDX icon
7
Becton Dickinson
BDX
$45.6B
$25M 2.75%
102,000
+19,000
+23% +$4.65M
COO icon
8
Cooper Companies
COO
$14.1B
$25M 2.74%
272,000
+84,000
+45% +$7.22M
ABBV icon
9
AbbVie
ABBV
$443B
$24M 2.64%
152,000
+22,000
+17% +$3.36M
COR icon
10
Cencora
COR
$60.6B
$23.7M 2.61%
149,000
-24,000
-14% -$3.81M
THC icon
11
Tenet Healthcare
THC
$20.5B
$23.6M 2.59%
410,000
-60,750
-13% -$3.38M
TMO icon
12
Thermo Fisher Scientific
TMO
$213B
$23.1M 2.53%
41,000
+1,000
+3% +$564K
MCK icon
13
McKesson
MCK
$100B
$22.2M 2.44%
62,000
+23,000
+59% +$8.31M
HCA icon
14
HCA Healthcare
HCA
$87.2B
$21.8M 2.39%
84,000
-6,000
-7% -$1.52M
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$15.9B
$21.7M 2.39%
150,000
+22,000
+17% +$3.25M
CI icon
16
Cigna
CI
$73.7B
$21.5M 2.36%
84,500
+22,500
+36% +$6.56M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.6B
$21.4M 2.35%
225,000
-29,000
-11% -$3.01M
GILD icon
18
Gilead Sciences
GILD
$162B
$21.1M 2.32%
259,000
-11,000
-4% -$911K
MDT icon
19
Medtronic
MDT
$109B
$18.6M 2.04%
235,000
-115,000
-33% -$9.37M
ABT icon
20
Abbott
ABT
$183B
$18.3M 2.01%
185,000
+68,000
+58% +$7.18M
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$27.5B
$14.8M 1.63%
76,000
+3,000
+4% +$631K
AXNX
22
DELISTED
Axonics, Inc. Common Stock
AXNX
$14.7M 1.62%
271,062
+41,062
+18% +$2.4M
HUM icon
23
Humana
HUM
$43.7B
$14.7M 1.61%
30,000
-9,000
-23% -$4.45M
SWAV
24
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$14.3M 1.58%
67,000
+20,000
+43% +$3.9M
BIIB icon
25
Biogen
BIIB
$30B
$13.1M 1.43%
47,500
+17,500
+58% +$4.84M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rhenman & Partners Asset Management held 97 positions worth $911M, down 5% from $958M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2023 filing shows 4 new, 33 increased, 45 reduced and 9 closed positions. Its largest new stake was Viking Therapeutics: 180,000 shares worth $3.12M. The largest sale was Eli Lilly, an estimated $32.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q1 2023 buy was Viking Therapeutics: 180,000 shares worth $3.12M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q1 2023, an estimated $18.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2023 reduction was Medtronic, cutting an estimated $9.37M.
  • Rhenman & Partners Asset Management fully exited Eli Lilly in Q1 2023, selling an estimated $32.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $911M portfolio in Q1 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 9 in Q1 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 5% quarter-over-quarter to $911M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2023, filed 12 May 2023.